Read more
Some 20 years ago the introduction of levodopa opened a new era in the treatment of Parkinson's disease. Although levodopa remains the single most effective drug for the treatment of this maladie, challeng ing therapeutic problems arise in many patients after several years of sustained treatment. Among these, fluctuations in motor performance and drug-induced involuntary movements are the most troublesome. The search for improved antiparkinsonian medications therefore con tinues and important new developments have already occurred, for example the introduction of the dopaminergic ergots and the selective MAO-B-inhibitor selegeline (deprenyl) into routine treatment. The International Workshop on Parkinson's Disease held in Inns bruckjIgls primarily considered a new compound with antiparkinsonian properties unrelated to any of the conventional drugs - the diphenyl ex piperidine compound budipine. The present volume records the perimental and clinical data on budipine presented at the meeting. The editors felt especially encouraged by the authorative biochemical, physiological, clinical and therapeutic reviews that were given at this symposium by outstanding experts in the field of extrapyramidal dis orders. Their inclusion should make this volume a valuable source of information on a variety of current research aspects into Parkinson's disease. InnsbruckjLondon, October 1984 The Editors v Contents James Parkinson and the Treatment of His Disease. G. Stern ....
List of contents
James Parkinson and the Treatment of His Disease.- Biochemical Neuropathology: A New Approach to Parkinson's Disease.- Clinical Neurophysiology of Parkinson's Disease.- Dopaminergic Agonists and Receptors: Their Relevance to the Treatment of Parkinson's Disease.- Brain Dopaminergic Receptor Changes in Parkinson's Disease in Relation to the Disease Process and Treatment.- Analysis of Akinesia.- Observations of Voluntarily Induced Automatic Motor Behaviour in Parkinsonism.- Significance of Mental Disorders in the Long-Term Treatment of Parkinson's Disease.- Treatment of Parkinson's Disease in Early and Late Phases.- Relevance of Dopaminergic Agonists and Antagonists to Parkinsonian Tremor.- Therapeutic Possibilities in On-Off Phenomena in Parkinson's Disease.- Target and Additive Drugs in the Treatment of Parkinson's Disease: A Pilot Study.- Pharmacologic Bases of Antiparkinsonian Therapy.- The Pharmacodynamics of Budipine on Central Neurotransmitter Systems.- Biochemical and Pharmacologic Aspects of the Mechanism of Action of Budipine.- Pharmacokinetics and Metabolism of Budipine in Animals and Humans.- Clinical Experience with Budipine in Parkinsonian Therapy.- Controlled Single-Blind Trial of Budipine. L-Dopa, and Amantadine in 102 Patients with Parkinson's Disease.- Open Clinical Trial of Budipine in 25 Tremor-Dominant Parkinsonian Patients.- Effect of Budipine on Parkinsonian Tremor Resistant to Other Antiparkinsonian Medication.- Budipine: A New Chemical Substance in the Treatment of Parkinson's Disease.- Observations on the Therapeutic Effect of Budipine on Parkinson's Disease.- Long-Term Treatment with Budipine.- Budipine Treatment of Neuroleptic-Induced Parkinsonism.- Randomized Double-Blind Trial of Budipine and Biperiden in Patients withNeuroleptic Extrapyramidal Symptoms.- The Effect of Budipine on the Rheology of the Blood.- EMG and Computer Analysis of Patients with Tremor and Rigidity Under Budipine Therapy.- Vigilance Study Using Electrooculographic and Electroencephalographic Methods After Acute Budipine Administration in Healthy Subjects.- Budipine in the Treatment of Extrapyramidal Disorders Not Related to Parkinson's Disease.
